Quarterly report pursuant to Section 13 or 15(d)

Unaudited Consolidated Statements of Operations and Comprehensive Loss

v3.19.1
Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
REVENUES    
Real property rental $ 266,626 $ 296,623
Medical related consulting services - related party 14,260
Development services and sales of developed products 3,278 11,290
Total Revenues 284,164 307,913
COSTS AND EXPENSES    
Real property operating expenses 230,759 210,274
Medical related consulting services - related party 13,091
Development services and sales of developed products 30,307 16,520
Total Costs and Expenses 274,157 226,794
REAL PROPERTY OPERATING INCOME 35,867 86,349
GROSS PROFIT FROM MEDICAL RELATED CONSULTING SERVICES 1,169
GROSS LOSS FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS (27,029) (5,230)
OTHER OPERATING EXPENSES:    
Advertising expenses 244,600
Compensation and related benefits 2,100,155 538,814
Professional fees 1,468,226 571,772
Research and development expenses 152,460
Other general and administrative 509,879 285,252
Total Other Operating Expenses 4,475,320 1,395,838
LOSS FROM OPERATIONS (4,465,313) (1,314,719)
OTHER INCOME (EXPENSE)    
Interest income 768 408
Interest expense (25,697) (236,986)
Interest expense - related party (1,944)
Loss from equity-method investment (12,743)
Other income 328
Total Other Expense, net (39,616) (236,250)
LOSS BEFORE INCOME TAXES (4,504,929) (1,550,969)
INCOME TAXES
NET LOSS (4,504,929) (1,550,969)
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (99,113) (69,390)
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS (4,405,816) (1,481,579)
COMPREHENSIVE LOSS:    
NET LOSS (4,504,929) (1,550,969)
OTHER COMPREHENSIVE INCOME
Unrealized foreign currency translation gain 43,482 52,838
COMPREHENSIVE LOSS (4,461,447) (1,498,131)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (100,311) (69,230)
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (4,361,136) $ (1,428,901)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:    
Basic and diluted $ (0.06) $ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic and diluted 73,690,461 69,781,733